Patents Examined by Venkataraman Balasubramanian
  • Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
    Patent number: 10611738
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: April 7, 2020
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • Glucokinase activators and methods of using same
    Patent number: 10604541
    Abstract: A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 31, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter Tai Wah Cheng, Wei Meng, Mark Liu, Bei Wang, Rulin Zhao
  • Sulfur scavenging materials
    Patent number: 10604539
    Abstract: Materials which react with (“scavenge”) sulfur compounds, such as hydrogen sulfide and mercaptans, are useful for limiting sulfur-induced corrosion. Surface-modified particles incorporating a hexahydrotriazine moiety are disclosed and used as sulfur scavengers. These surface-modified particles are used a filter media in fixed filter systems and as additives to fluids including sulfur compounds. The hexahydrotriazine moiety can react with sulfur compounds in such a manner as to bind sulfur atoms to the surface-modified particles, thus allowing removal of the sulfur atoms from fluids such as crude oil, natural gas, hydrocarbon combustion exhaust gases, sulfur polluted air and water. The surface-modified particles may, in general, be sized to allow separation of the particles from the process fluid by sedimentation, size-exclusion filtration or the like.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 31, 2020
    Assignee: International Business Machines Corporation
    Inventors: Dylan J. Boday, Jeannette M. Garcia, James L. Hedrick, Rudy J. Wojtecki
  • Organic compounds
    Patent number: 10597394
    Abstract: This invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: March 24, 2020
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Peng Li, Lawrence P. Wennogle, Robert Davis
  • Adenine conjugate compounds and their use as vaccine adjuvants
    Patent number: 10597397
    Abstract: The present specification relates to adenine conjugate compounds represented by the formula (1), wherein A, L1, L2, X1, R1, R2, R3, and m are as defined herein, or their pharmaceutically acceptable salts. Compounds of formula (1) have immunostimulating properties and may therefore be useful in therapy, for example as vaccine adjuvants. The present specification also relates to a process for preparing adenine conjugate compounds and pharmaceutically acceptable salts thereof, and to pharmaceutical compositions comprising adenine conjugate compounds and their pharmaceutically acceptable salts.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 24, 2020
    Assignee: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Hitoshi Ban, Yukihiro Nishio, Padma Malyala, Bilikallahalli K. Muralidhara, Marcus Wong
  • IRAK4 inhibiting agents
    Patent number: 10577367
    Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: March 3, 2020
    Assignee: BIOGEN MA INC.
    Inventors: Timothy Chan, Kevin Guckian, Tracy Jenkins, Jermaine Thomas, Jeffery Vessels, Gnanasambandam Kumaravel, Robert Meissner, Joseph Lyssikatos, Brian Lucas, Irina Leaf, Jeremy Duffield
  • Process for preparing methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate and its purification for use as pharmaceutically active compound
    Patent number: 10570130
    Abstract: The present invention relates to a process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate of the formula (I) and to a process for purifying the crude product of the compound of the formula (I) for use as pharmaceutically active compound, where, for purification, methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate sulphinyldimethane (1:1), i.e. a compound of the formula (II), is isolated as intermediate or is generated as intermediate in this purification process, if appropriate present in a mixture.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: February 25, 2020
    Assignee: Adverio Pharma GmbH
    Inventors: Franz-Josef Mais, Joachim Rehse, Winfried Joentgen, Konrad Siegel
  • Boronic acid derivatives and therapeutic uses thereof
    Patent number: 10570159
    Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, ?-lactamase inhibitors (BLIs).
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: February 25, 2020
    Assignee: Qpex Biopharma, Inc.
    Inventors: Scott J. Hecker, Raja K. Reddy, Tomasz Glinka, Olga Rodny
  • Tricyclic heterocylic derivatives
    Patent number: 10570149
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of ATR, and can be employed for the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: February 25, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Lars Burgdorf, Dieter Dorsch, Christos Tsaklakidis
  • Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof
    Patent number: 10570141
    Abstract: The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: February 25, 2020
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
    Inventors: Shulong Wang, Kuncheng Chen, Xijie Liu, Yuandong Hu, Bo Liu, Yong Peng, Hong Luo, Yongxin Han, Shanchun Wang, Mei Liu, Hongjiang Xu
  • Selective PI3K delta inhibitors
    Patent number: 10570142
    Abstract: The present invention relates to selective inhibitors of PI3K delta protein kinases, methods of preparing them, pharmaceutical compositions containing them and methods of treatment and/or prevention of kinase mediated diseases or disorders with them.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: February 25, 2020
    Assignee: Rhizen Pharmaceuticals SA
    Inventors: Swaroop K. Vakkalanka, Meyyappan Muthuppalaniappan, Dhanapalan Nagarathnam
  • Compound and organic photoelectric device, image sensor and electronic device including the same
    Patent number: 10566544
    Abstract: Example embodiments provide a compound of Chemical Formula 1, and an organic photoelectric device, an image sensor, and an electronic device including the same.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: February 18, 2020
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Hiromasa Shibuya, Tatsuya Imase, Rie Sakurai, Xavier Bulliard, Hyesung Choi, Tadao Yagi, Sung Young Yun, Gae Hwang Lee, Kwang Hee Lee, Dong-Seok Leem, Yeong Suk Choi
  • 4-oxo-3,4-dihydro-1,2,3-benzotriazine modulators of GPR139
    Patent number: 10561662
    Abstract: The present invention provides a method for treating a disease, disorder or condition associated with GPR139 using compounds of formula 1: which are agonists of GPR139, certain compounds encompassed by formula 1, pharmaceutical compositions thereof, processes for making the compounds, and intermediates thereof.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: February 18, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen Hitchcock, Betty Lam, Holger Monenschein, Holly Reichard
  • Process for the synthesis of amide bonds with the aid of novel catalysts
    Patent number: 10544186
    Abstract: The invention relates to a process for the production of amide bonds, in particular peptide bonds, with the aid of novel amide linking reagents containing an anion of the formula (I), to the novel reagents, and to the preparation thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: January 28, 2020
    Assignee: Merck Patent GmbH
    Inventors: Nikolai Mykola Ignatyev, Walter Frank, Peter Barthen, Myroslav Vysotsky
  • Bis-biotinylation tags
    Patent number: 10544449
    Abstract: Multi-biotinylated reactants are provided which can be used in divalent complexes for various applications such as colocalization, labeling, immobilization, and purification. Methods for constructing, purifying, and using the bis-biotinylated reactants are also provided. In certain embodiments, two bis-biotinylated reactants are bound to a single streptavidin tetramer to provide a complex having a 1:1 stoichiometry with respect to the bis-biotinylated reactants.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 28, 2020
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Gene Shen, Natasha Popovich, Erik Miller, Satwik Kamtekar, Keith Bjornson, Jeremiah Hanes, Stephen Yue, Lubomir Sebo, Zhong Wang
  • Heterocyclic systems and pharmaceutical applications thereof
    Patent number: 10526343
    Abstract: Novel heterocyclic fused systems are disclosed herein which possess numerous biological activities, including but not limited to antibacterial activity, and usefulness to the treatment of many disease states, such as pathogenic infections. In particular, new imidazoles are disclosed along with related processes of preparation and methods of use as antibacterial agents. The disclosed compounds were found to be active against several Gram-positive bacteria, including Enterococcus faecalis and Bacillus subtilis, and were also found to be active against several species of multi-drug resistant Staphylococcus, such as S. aureus, S. saprophyticus, S. haemolyticus, and S. epidermidis.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: January 7, 2020
    Assignee: UNIVERSITY OF SHARJAH
    Inventors: Taleb H. Altel, Raafat A El-Awady, Srinivasulu Vunnam, Farah Ibrahim Al-Marzooq
  • Thienopyrimidines and uses thereof
    Patent number: 10526341
    Abstract: Described herein are thienopyrimidine compounds of Formula (I), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the thienopyrimidine compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., brain tumors such as DIPGs) in a subject. The invention further provides an embryonic stem cell-based tumor cell model, which can be used for drug screening and disease target identification.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 7, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Viviane Tabar, Kosuke Funato
  • Amino acid acylation reagents and methods of using the same
    Patent number: 10526344
    Abstract: Provided herein are compounds useful for appending amino acids to nucleophiles.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 7, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Thomas Nittoli, Srinath Thirumalai Rajan, Thomas P. Markotan, Nareshkumar Jain
  • Synthesis of polycyclic-carbamoylpyridone compounds
    Patent number: 10519168
    Abstract: Methods of making compounds of Formula I are disclosed:
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: December 31, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: John Enquist, Jr., Nolan Griggs, Christopher Hale, Norihiro Ikemoto, Andrew W. Waltman
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 10519146
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: December 31, 2019
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, David John Kopecky, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Nobuko Nishimura, Youngsook Shin, Nuria A. Tamayo, John Gordon Allen, Jennifer Rebecca Allen